Martin Kuster
Novartis
6 Papers
8 Citations
Martin Kuster is an academic researcher from Novartis. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Predictors of success for smoking cessation at the workplace: a longitudinal study.
Daiana Stolz,Andreas Scherr,Bruno Seiffert,Martin Kuster,Anja Meyer,Karl-Olov Fagerström,Michael Tamm +6 more
TL;DR: A comprehensive smoking cessation intervention at the workplace achieves high, stable, long-term abstinence rates and Elderly, well-educated employees with breathlessness on exertion have higher odds of quitting smoking.
Predictors of marked weight gain in a population of health care and industrial workers following smoking cessation
Andreas Scherr,Bruno Seifert,Martin Kuster,Anja Meyer,Karl-Olov Fagerstroem,Michael Tamm,Daiana Stolz +6 more
TL;DR: A comprehensive multi-institutional smoking cessation program for health care and industrial workers employed at University Hospital Basel and two local health industry companies found marked weight gain following smoking cessation was characterized by a wide margin of changes.
Cancer risk of immunosuppressants in manufacturing.
Ester Lovsin Barle,Gian Christian Winkler,Peter Ulrich,Christopher Perino,Martin Kuster,Alessandro Probst,Silke Thielen,Rudolf Bechter +7 more
TL;DR: If the exposure to cyclosporine at the workplace is below the threshold necessary to induce immunosuppression, the risk to develop cancer is negligible, and the appropriate hazard classification for regulatory purposes is determined.
7
Classification of dermal sensitizers in pharmaceutical manufacturing
Gian Christian Winkler,Christopher Perino,Selene Araya,Rudolf Bechter,Martin Kuster,Ester Lovsin Barle +5 more
TL;DR: This work examined, if alternative methods could replace presently used animal tests for identification of ACD in pharmaceutical development and manufacturing, without apparent loss of worker health, in line with regulations.
3
Pos0270 burden of covid-19 in patients with inflammatory rheumatic diseases: insights from a swiss app-based survey
TL;DR: Goldman et al. as mentioned in this paper found that after around two years of the COVID-19 pandemic, the burden of inflammatory rheumatic diseases in Switzerland is generally low, although it appears higher in patients with JAKi and rituximab, and that for a minority the quality of life still remains impacted.